Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Karyopharm Therapeutics Inc. hopes to advance lead compound KPT-330 through pivotal trials for at least two cancer indications with funds from last week's $48.2 million series B round.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury